PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34476566-4	2021	In the present study, we detected the DNA methylation in the promoter regions of five representative dopaminergic system genes (DRD1, DRD2, SLC6A3, TH, and COMT) between 120 patients with heroin use disorder in methadone maintenance treatment (MMT) program and 111 healthy controls.	Methadone	211-220	dopamine receptor D2	Homo sapiens	134-138	
29495204-1	2018	Objective: To investigate the association between three single nucleotide polymorphism (SNP) genes DRD2 (rs1800497, rs6275, and rs1799978) and the dosage used on methadone maintenance treatment (MMT).	Methadone	162-171	dopamine receptor D2	Homo sapiens	99-103	
33828379-0	2020	Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy.	Methadone	88-97	dopamine receptor D2	Homo sapiens	13-17	
33828379-3	2020	The objective of this study was to investigate the influence of DRD2 polymorphisms on the clinical outcomes of opioid-dependent patients on methadone maintenance therapy (MMT).	Methadone	140-149	dopamine receptor D2	Homo sapiens	64-68	
30928885-0	2019	The polymorphism of dopamine D2 receptor TaqIA gene is associated with brain response to drug cues in male heroin-dependent individuals during methadone maintenance treatment.	Methadone	143-152	dopamine receptor D2	Homo sapiens	20-40	
29495204-0	2018	[Association between DRD2 gene polymorphisms and the dosage used on methadone maintenance treatment program].	Methadone	68-77	dopamine receptor D2	Homo sapiens	21-25	
29495204-5	2018	And DRD2 SNPs were genotyped to explore the relationship between polymorphism of DRD2 gene and the dosage of methadone maintenance treatment.	Methadone	109-118	dopamine receptor D2	Homo sapiens	81-85	
29495204-10	2018	Conclusion: DRD2 rs6275 was associated with dosage of methadone used for the MMT patients.	Methadone	54-63	dopamine receptor D2	Homo sapiens	12-16	
23651024-5	2013	RESULTS: Out of the 110 variants analyzed, 12 SNPs (in BDNF, NTRK2, OPRM1, DRD2 and ANKK1) were associated with methadone dose (nominal p < 0.05).	Methadone	112-121	dopamine receptor D2	Homo sapiens	75-79	
25358852-3	2015	OBJECTIVES: We evaluated the consequences of two administration patterns of methadone and buprenorphine on striatal dopamine D1 (D1R) and D2 (D2R) receptor levels.	Methadone	76-85	dopamine receptor D2	Homo sapiens	142-145	
20575771-3	1999	The present study compares the frequency of the A1 allele of the DRD2 gene among 37 patients presenting to a hepatitis clinic for treatment of hepatitis C, 23 hepatitis C-negative drug-abusing patients maintained on methadone and 33 non-drug-abusing controls.	Methadone	216-225	dopamine receptor D2	Homo sapiens	65-69	
16583408-0	2006	Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments.	Methadone	55-64	dopamine receptor D2	Homo sapiens	24-28	
16583408-1	2006	The TaqI A polymorphism (A(1)) of the dopamine D(2) receptor gene (DRD2), although not a specific predictor of opioid dependence, has been strongly associated with high levels of prior heroin use and poor treatment outcomes among methadone maintenance patients.	Methadone	230-239	dopamine receptor D2	Homo sapiens	38-60	
16583408-1	2006	The TaqI A polymorphism (A(1)) of the dopamine D(2) receptor gene (DRD2), although not a specific predictor of opioid dependence, has been strongly associated with high levels of prior heroin use and poor treatment outcomes among methadone maintenance patients.	Methadone	230-239	dopamine receptor D2	Homo sapiens	67-71	
11054765-0	2000	The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment.	Methadone	106-115	dopamine receptor D2	Homo sapiens	4-26	
11054765-8	2000	The results indicate that DRD2 variants are predictors of heroin use and subsequent methadone treatment outcome and suggest a pharmacogenetic approach to the treatment of opioid dependence.	Methadone	84-93	dopamine receptor D2	Homo sapiens	26-30	
21902500-0	2011	Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.	Methadone	81-90	dopamine receptor D2	Homo sapiens	67-71	
21902500-4	2011	On the other hand, carriers of the variant DRD2 -214A>G or 939C>T allele had a twofold chance of requiring a lower methadone dose than noncarriers (p = 0.001).	Methadone	121-130	dopamine receptor D2	Homo sapiens	43-47	
21902500-5	2011	Proportional odds regression with adjustment of cofactors demonstrated that ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genetic variants were jointly correlated with optimal methadone dose (adjusted r(2) = 53%).	Methadone	167-176	dopamine receptor D2	Homo sapiens	108-112	
20514076-1	2011	beta-Arrestin2 (ARRB2) is a component of the G-protein-coupled receptor complex and is involved in mu-opioid and dopamine D(2) receptor signaling, two central processes in methadone signal transduction.	Methadone	172-181	dopamine receptor D2	Homo sapiens	113-135	
19373123-0	2009	Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution.	Methadone	139-148	dopamine receptor D2	Homo sapiens	26-46	
19373123-2	2009	Here, we comprehensively analyzed the DRD2 gene locus, and in addition, the ANKK1 rs1800497C>T single nucleotide polymorphism (SNP), formerly known as "dopamine D2 receptor Taq1A C>T polymorphism", for associations with the risk of opiate addiction and the methadone dosage requirements.	Methadone	263-272	dopamine receptor D2	Homo sapiens	155-175	
19373123-6	2009	The average and maximum daily methadone doses were significantly associated with the DRD2 rs6275C>T SNP (P=0.016 and 0.005 for average and maximum dose, respectively).	Methadone	30-39	dopamine receptor D2	Homo sapiens	85-89	
19373123-9	2009	CONCLUSION: On the basis of an analysis spanning the whole gene locus, from the DRD2 promoter to the ANKK1 rs1800497C>T polymorphism, DRD2 genetic polymorphisms modulate both the risk of opiate addiction, leading to the necessity of methadone substitution therapy, and the course of this therapy in terms of dosage requirements.	Methadone	236-245	dopamine receptor D2	Homo sapiens	137-141